Chinese vaccine developer based in Chengdu; specific vaccine product line not fully established from available knowledge.
Chinese vaccine developer based in Chengdu; specific vaccine product line not fully established from available knowledge.
Moat: none
Headquarters: Chengdu, China · Employees: 451
Size Chengdu Olymvax Biopharmaceuticals (688319.SS) is a China Health Care company (Biotechnology) with a market value of $1.51B, the 1507th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥24.71 on 18 Nov 2026.
Performance Over six months the shares fell 37.0%, against -2.8% for the median peer and -20.0% for the China market (cap-weighted) — 4th lowest of 20 in its peer set.
Growth Revenue grew 12.3% over the last twelve months (peer median +25.4%); the operating margin is 8.2% (peer median -9.6%).
Valuation It trades at 13.1× enterprise value to sales against a peer median of 10.1× (8th most expensive of 18).
Capital Return on invested capital runs 5.4 points below its cost of capital (11.5% WACC).
Next results Next results expected around 29 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥796M | CN¥702M | CN¥587M | CN¥494M | CN¥544M |
| Revenue growth | — | +19% | +19% | -9% | — |
| Gross profit | CN¥746M | CN¥624M | CN¥532M | CN¥443M | CN¥488M |
| EBITDA | n/a | CN¥76.0M | CN¥57.4M | CN¥37.6M | CN¥43.3M |
| Net income | -CN¥32.0M | CN¥22.3M | CN¥20.8M | CN¥17.6M | CN¥26.6M |
| Free cash flow | -CN¥106M | CN¥7.18M | -CN¥216M | -CN¥125M | -CN¥222M |
| Capital expenditure | CN¥125M | CN¥98.8M | CN¥207M | CN¥170M | CN¥201M |
| Total debt | CN¥509M | CN¥433M | CN¥362M | CN¥238M | CN¥139M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 688319.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -8.6% | -10.9% | 9th highest of 21 |
| 6-month return | -37.0% | -2.8% | 4th lowest of 20 |
| Distance from 52-week high | -45.0% | -42.7% | 10th lowest of 21 |
| Revenue growth (TTM) | +12.3% | +25.4% | 6th lowest of 19 |
| Operating margin | 8.2% | -9.6% | 7th highest of 19 |
| EV / Sales | 13.1× | 10.1× | 8th most expensive of 18 |
| ROIC minus cost of capital | -5.4 pp | -15.4 pp | 6th highest of 14 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Chengdu Olymvax Biopharmaceuticals 688319.SS | China | $1.51B | -37% | +12% | 8% | 13.1× | n/a | n/a |
| Korsana Biosciences KRSA | United States | $1.52B | +54% | -64% | -5,277% | 1,058.7× | n/a | n/a |
| TLC BioSciences 7924.TWO | Taiwan | $1.50B | n/a | n/a | n/a | n/a | n/a | n/a |
| Kailera Therapeutics KLRA | United States | $1.53B | -41% | n/a | n/a | n/a | n/a | n/a |
| Precigen PGEN | United States | $1.53B | 0% | +2,388% | 21% | 10.1× | n/a | n/a |
| Peptron 087010.KS | South Korea | $1.49B | -68% | -13% | -488% | 359.6× | n/a | n/a |
| Mesoblast MSB.AX | Australia | $1.49B | -17% | +556% | -43% | 12.8× | n/a | n/a |
| Nurix Therapeutics NRIX | United States | $1.54B | -14% | +739% | 41% | 0.8× | n/a | n/a |
| Fujian Haixi Pharmaceuticals 2637.HK | Hong Kong | $1.47B | -32% | +25% | 33% | n/a | n/a | n/a |
| UroGen Pharma URGN | United States | $1.46B | -1% | +159% | -12% | 6.3× | n/a | n/a |
| Wuhan Healthgen Biotechnology 688765.SS | China | $1.46B | -51% | +90% | -297% | 205.0× | n/a | n/a |
| Vir Biotechnology VIR | United States | $1.57B | +3% | +1,696% | -70% | 4.0× | n/a | n/a |
| Immunocore Holdings Plc Shs Sponsored American Depositary Shares Repr 1 Sh IMCR | United States | $1.44B | -7% | +13% | -7% | 2.3× | n/a | n/a |
| Nanjing Vazyme Biotech 688105.SS | China | $1.42B | +25% | +16% | -5% | 4.9× | 39.4% | -2.5% |
| uniQure QURE | United States | $1.42B | -17% | +28% | -1,027% | 65.4× | n/a | n/a |
| PolyPeptide PPGN.SW | Switzerland | $1.61B | +7% | +22% | 7% | 3.4× | n/a | n/a |
| Absci ABSI | United States | $1.41B | +65% | -47% | -9,155% | 835.7× | n/a | n/a |
| PELL Bio-Med Technology 6949.TW | Taiwan | $1.62B | +28% | +8% | -1,463% | 1,650.2× | n/a | n/a |
| Hitgen 688222.SS | China | $1.62B | -3% | +42% | 27% | 14.4× | 33.2% | +16.8% |
| Alvotech ALVO | United States | $1.62B | +38% | -14% | 12% | 6.4× | n/a | n/a |
| ANI Pharmaceuticals ANIP | United States | $1.62B | -13% | +26% | 15% | 1.7× | -7.6% | +33.5% |